Meeting
2021 ASCO Annual Meeting
Pre-therapeutic dihydropyridimidine dehydrogenase (DPD) deficiency screening: Impact on fluoropyrimidine dose reduction at the second chemotherapy cycle and on early severe toxicity.
Authors
Côme De Metz
Hôpital Victor Provo, Roubaix, France
Côme De Metz , Benjamin Hennart , Marie-Cecile Le Deley , Pierre-Yves Cren , Christophe Desauw , Vincent Bourgeois , Fredrik Laestadius , Emilia Rad , Loic Lebellec , Nicolas Penel , Aurelien Carnot
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Pharmacology/Pharmacodynamics/Pharmacogenetics
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 3096)
DOI
10.1200/JCO.2021.39.15_suppl.3096
Abstract #
3096
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Real-world experience of an in-house dihydropyrimidine dehydrogenase (DPYD) genotype test to guide fluoropyrimidine (FP) dosing at a multisite cancer hospital.
First Author: Jai Narendra Patel
Poster
2021 ASCO Quality Care Symposium
Sustainability and clinical outcomes of routine screening for pathogenic DPYD gene variants prior to fluoropyrimidine (FP) chemotherapy for gastrointestinal (GI) cancer.
First Author: Gabriel A. Brooks
Poster
2012 Gastrointestinal Cancers Symposium
DPD deficiency: Medicoeconomic evaluation of pretreatment screening of 5-FU toxicity.
First Author: Sory Traoré
Poster
2023 ASCO Quality Care Symposium
Implementing a high-reliability, system-wide program for pre-emptive DPD deficiency testing for patients planned for a systemic fluoropyrimidine.
First Author: Garrett Rompelman